Inovio Pharmaceuticals Inc. (NYSEMKT:INO) had recently announced the name of E.J. Brandreth for the post of Vice President of quality. Brandreth would report to Dr. Niranjan Sardesai, who is the Chief Operating Officer of Inovio Pharmaceuticals Inc. (NYSEMKT:INO). Brandrethhas a proven track record of growth in field of quality for varied pharma companies, making him the first choice for the coveted post of VP of Quality in Inovio Pharmaceuticals Inc. (NYSEMKT:INO). The roles and responsibilities for the new VP would include ensuring that the proper quality and the compliance functions of the company would be strictly adhered to, especially in light of numerous clinical trials taking place which are in varied stages. He would also play an important role in ensuring quality in various operational areas of the company for making the way smoother for the scheduled DNA vaccines as well as immunotherapies. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares after opening at $3.00 moved to $3.08 on last trade day and at the end of the day closed at $2.80. Company price to sales ratio in past twelve months was calculated as 49.70 and price to cash ratio as 12.76. Inovio Pharmaceuticals Inc (NYSEMKT:INO) showed a negative weekly performance of -19.77%.
Alkermes Plc (NASDAQ:ALKS), a $5.93 billion drug company, announced that its experimental drug intended for treatment of schizophrenia, met late-stage study goal with solid results. The company stated that the drug was able to significantly reduce severity of schizophrenia symptoms among the selected patients in which it was tried against a placebo. Alkermes Plc (NASDAQ:ALKS) shares advanced 2.38% in last trading session and ended the day on $42.08. ALKS return on equity ratio is recorded as 2.10% and its return on assets is 1.40%. Alkermes Plc (NASDAQ:ALKS) yearly performance is 83.28%.
Investment analysts at Canaccord Genuity lowered their price target on shares of The Spectranetics (NASDAQ:SPNC) from $35.00 to $30.00 in a note issued to investors on Tuesday, Stock Ratings Network.com reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price objective suggests a potential upside of 14.90% from the company’s current price. The Spectranetics Corporation (NASDAQ:SPNC) shares moved down -11.87% in last trading session and was closed at $23.01, while trading in range of $22.00-$24.20. The Spectranetics Corporation (NASDAQ:SPNC) year to date performance is -7.96%.
TherapeuticsMD Inc (NYSEMKT:TXMD), announced positive outcomes of a rabbit irritation study for TX 004-HR (formerly referred to as TX 12-004-HR), a rapidly acting estrogen vaginal preparation capsule (VagiCap).This toxicity study involved vaginal administration of VagiCap in New Zealand white female rabbits. The study demonstrated that TX 004-HR was “non-irritant” following a 28-day repeated application to the vaginal mucosa. TherapeuticsMD Inc (NYSEMKT:TXMD) weekly performance is -23.34%. On last trading day company shares ended up $4.63. TherapeuticsMD Inc (NYSEMKT:TXMD)distance from 50-day simple moving average is -29.49%. Analysts mean target price for the company is $8.75.